MedTrace Logo

Botulinum Toxin A for the Treatment of Keratoconus

NCT01691651 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-10-21

No results posted yet for this study

Summary

The purpose of this study is to associate the use of botulinum toxin type A for patients with keratoconus to demonstrate that tension eyelid has an important role in disease progression.

Conditions

  • Keratoconus

Interventions

PROCEDURE

Subcutaneous injection of botulinum toxin type A

Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.

DRUG

Botulinum Toxin Type A

2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.

Sponsors & Collaborators

  • Federal University of São Paulo

    lead OTHER

Principal Investigators

  • Adimara C Renesto, MD · Federal University of São Paulo

  • Teissy H Osaki, MD · Federal University of São Paulo

  • Midori H Osaki, MD · Federal University of São Paulo

  • Mauro Q Campos, MD · Federal University of São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01691651 on ClinicalTrials.gov